Skip to main content
SNOA logo

Sonoma Pharmaceuticals, Inc. (SNOA) Stock Price & Analysis

Sonoma Pharmaceuticals, Inc. (SNOA) — MoonshotScore 25/100 (Weak band), calculated Nov 18, 2026. Price $0.8097 (-2.21%), as of the Nov 19, 2026 trading session; market cap $4.10M.

Educational signal · not a buy or sell recommendation · How to read this

$0.8097 −$0.0183 (-2.21%) Market Cap $4.10M

Sonoma Pharmaceuticals, Inc. · SNOA · NASDAQ

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for various applications. Their products are used in wound care, animal health, eye care, oral care, and dermatology across the United States, Latin America, Europe, and internationally.

Price as of Nov 19, 2026

Key Statistics

25 of 100

MoonshotScore v2 · Sonoma Pharmaceuticals (SNOA)

Weak
Business Quality Solid (69)
Financial Safety Fragile (15)
Valuation Fair (71)
Growth Durability Fading (38)
Momentum Slipping (31)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet and weak growth. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Fading; Momentum: Slipping.

  • quarterly revenue $6M (Q1 FY2027, quarter ended Jun 30, 2026)
  • EPS beat 4 of the last 8 reports
  • Altman Z -14.30 · Piotroski F 3

Holding back: balance-sheet strain, weak price trend

Helping: business quality, an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SNOA (58 recorded, newest six shown)
RecordedScoreBand
25Weak
24Weak
24Weak
25Weak
25Weak
25Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.8097
Change on the day-2.21%
Market capitalisation$4.10M—
Shares traded on the day34.4K

Price & events

Other perspectives

Council score for Sonoma Pharmaceuticals (SNOA): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Moderate
Growth Durability Weak
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 12, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Moderate
ROE Negative
Gross Margin Neutral

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Sonoma Pharmaceuticals (SNOA), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Sonoma Pharmaceuticals, Inc. (SNOA) is listed on NASDAQ. It employs 10 people. In Q1 FY2027 it reported revenue of $6M and net income of -$330,000. The market values it at $4.10M.

2 · Latest results

What do the latest results show for Sonoma Pharmaceuticals (SNOA)?

Short answer · as of

The most recent reported quarter, Q1 FY2027, carried revenue of $6M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2027$6M-$330,000-$0.09 (diluted)
Q4 FY2026$6M-$581,000-$0.33 (diluted)
Q3 FY2026$4M-$819,000-$0.48 (diluted)
Q2 FY2026$6M-$534,000-$0.32 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sonoma Pharmaceuticals (SNOA)?

Short answer · as of

The MoonshotScore pillars rate business quality, an attractive price as strengths. What is holding it back is balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -14.30 · Piotroski F 3. Trailing ratios: ROE -36.4% · ROA -10.5% · current ratio 3.48 · earnings yield -33.6% · free-cash-flow yield -50.5%.

Data-derived red flags

  • Listing risk — at $0.8097 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -14.30 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-36.4%) — the business is not currently generating profit on shareholder capital.
5 · Peer comparison

How does Sonoma Pharmaceuticals compare with its peers?

Short answer

Sonoma Pharmaceuticals's score ranks tied for 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Incannex Healthcare Limited (IXHL) Same industry, near in market value$1.74 Nov 19, 2026$21.8M48 5-pillar Nov 18, 2026
TherapeuticsMD, Inc. (TXMD) Same industry, near in market value$1.81 Nov 19, 2026$21.0M34 5-pillar Nov 18, 2026
Universe Pharmaceuticals Inc. (UPC) Same industry, near in market value$1.36 Nov 19, 2026$6.83M32 5-pillar Nov 18, 2026
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Same industry, near in market value$3.90 Nov 19, 2026$18.6M32 5-pillar Nov 18, 2026
Quantum BioPharma Ltd. (QNTM) Same industry, near in market value$1.42 Nov 19, 2026$9.13M30 5-pillar Nov 18, 2026
Sonoma Pharmaceuticals (SNOA) — this page$0.8097$4.10M25
Biofrontera Inc. (BFRI) Named competitor$0.57 Nov 19, 2026$10.2M25 5-pillar Nov 18, 2026
Rockwell Medical, Inc. (RMTI) Same industry, near in market value$6.26 Nov 19, 2026$24.9M25 5-pillar Nov 18, 2026
Aytu BioPharma, Inc. (AYTU) Same industry, near in market value$2.66 Nov 19, 2026$28.9M25 5-pillar Nov 18, 2026
CPHI (CPHI) Named competitor$0.50 Nov 19, 2026$21.7M23 5-pillar Nov 18, 2026
cbdMD, Inc. (YCBD) Same industry, near in market value$0.38 Nov 19, 2026$5.10M23 5-pillar Nov 18, 2026
COSM (COSM) Same industry, near in market value$2.87 Nov 19, 2026$14.4M23 5-pillar Nov 18, 2026
SCYNEXIS, Inc. (SCYX) Same industry, near in market value$2.60 Nov 19, 2026$25.9M23 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 9, 2026

Transactions
6
Identified insiders
6
Purchases
0
Sales
0
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SNOA in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SNOA in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Sonoma Pharmaceuticals (SNOA)?

Read these with our analysis →

Sonoma Pharmaceuticals Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the SNOA research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for SNOA?

SNOA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for various applications.

Is SNOA a good stock to buy?

Stock Expert AI does not rate SNOA buy, sell or hold. Sonoma Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SNOA stock price today?

The last price recorded for Sonoma Pharmaceuticals, Inc. (SNOA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Sonoma Pharmaceuticals, Inc. do?

Their core business revolves around leveraging HOCl technology to create solutions for wound care, animal health, eye care, oral care, and dermatological conditions.

What are the key factors to evaluate for SNOA?

Sonoma Pharmaceuticals, Inc. (SNOA) holds a MoonshotScore in the low range. Sonoma Pharmaceuticals focuses on stabilized hypochlorous acid (HOCl) products, a niche market within the broader healthcare sector. Not financial advice.

How frequently does SNOA data refresh on this page?

SNOA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SNOA's recent stock price performance?

Sonoma Pharmaceuticals, Inc. (SNOA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary HOCl technology platform. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SNOA overvalued or undervalued right now?

Sonoma Pharmaceuticals, Inc. (SNOA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of SNOA?

Fractional-share availability for Sonoma Pharmaceuticals, Inc. (SNOA) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 9 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.